BRAF and thyroid gland undifferentiated (anaplastic) carcinoma: Targeting the BRAF V600E oncogene with a single BRAF inhibitor shows response rates of approximately 50% in melanomas or non-small cell lung cancers, but no activity in colorectal cancers, anaplastic thyroid cancers, or several other types of cancers36–38.